The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.
about
The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementiaOxidative stress-induced signaling pathways implicated in the pathogenesis of Parkinson's diseaseExploring Music-Based Rehabilitation for Parkinsonism through Embodied Cognitive ScienceIs Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?Rescue from tau-induced neuronal dysfunction produces insoluble tau oligomersSubstitution p.A350V in Na⁺/Mg²⁺ exchanger SLC41A1, potentially associated with Parkinson's disease, is a gain-of-function mutationThe cybrid model of sporadic Parkinson's disease.Neuromolecular imaging, a nanobiotechnology for Parkinson's disease: advancing pharmacotherapy for personalized medicine.Mitochondrial quality, dynamics and functional capacity in Parkinson's disease cybrid cell lines selected for Lewy body expression.Adsorption of α-synuclein to supported lipid bilayers: positioning and role of electrostaticsCopper-triggered aggregation of ubiquitin.A neurotoxic phosphoform of Elk-1 associates with inclusions from multiple neurodegenerative diseases.Early aggregation steps in alpha-synuclein as measured by FCS and FRET: evidence for a contagious conformational change.Glycoproteomics in neurodegenerative diseases.The interaction of alphaB-crystallin with mature alpha-synuclein amyloid fibrils inhibits their elongation.Metabolic Investigations of the Molecular Mechanisms Associated with Parkinson's DiseaseManganese and Parkinson's disease: a critical review and new findings.Cardiac sympathetic denervation in 6-OHDA-treated nonhuman primates.The AAA-ATPase VPS4 regulates extracellular secretion and lysosomal targeting of α-synuclein.The circadian clock and pathology of the ageing brain.Gene expression profiles in Parkinson disease prefrontal cortex implicate FOXO1 and genes under its transcriptional regulation.Evaluation of Parkinson disease risk variants as expression-QTLs.α-Synuclein and anti-α-synuclein antibodies in Parkinson's disease, atypical Parkinson syndromes, REM sleep behavior disorder, and healthy controlsMembrane lipid co-aggregation with α-synuclein fibrils.Acceleration of α-synuclein aggregation by exosomes.Proteomic identification of proteins in the human brain: Towards a more comprehensive understanding of neurodegenerative diseaseStudying the system-level involvement of microRNAs in Parkinson's diseaseOxidative stress in neurodegenerative diseases.Nitrosative stress-induced Parkinsonian Lewy-like aggregates prevented through polyphenolic phytochemical analog interventionSolid Microneedles for Transdermal Delivery of Amantadine Hydrochloride and Pramipexole Dihydrochloride.Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease.Distribution of α-synuclein in the spinal cord and dorsal root ganglia in an autopsy cohort of elderly persons.α-Synuclein and nonhuman primate models of Parkinson's diseaseCatecholamines and Neurodegeneration in Parkinson's Disease-From Diagnostic Marker to Aggregations of α-Synuclein.Lewy body-like α-synuclein aggregates resist degradation and impair macroautophagy.Changes in the sympathetic innervation of the gut in rotenone treated mice as possible early biomarker for Parkinson's disease.Complexity of dopamine metabolism.Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum.What determines the molecular composition of abnormal protein aggregates in neurodegenerative disease?Proteomics of human neurodegenerative diseases
P2860
Q22252705-9C8C1E58-2923-4AD2-B8F1-E4A971F64B0BQ24337079-4BC6BB91-81F0-4A21-98BE-57316162B360Q26779648-80B5851B-F160-4158-9E16-2AAF1E54F791Q26801733-F14B6319-1BC0-4482-A654-32FAD3B80BC1Q27305025-76A1A0B3-5246-46C3-889B-4F23DBA94E47Q28115295-965E1DA8-B009-4BE4-8AF4-5B2152D15628Q28751790-E4F90CD6-9BE0-472A-A06B-9636B753A6FFQ30394681-B57E21E1-7990-4A47-8BB6-F9B45C1CC0A2Q30422362-79BBC48E-0924-4CA1-B0A0-A3F59E9E120AQ30428288-29EC54E8-DECB-4124-9CC2-8C20E812B0E8Q33503629-452C1E34-826F-48F8-998C-AB859132FC43Q33528960-D5F28BDB-BC64-41C2-813E-92A25C7D6EB2Q33550002-9C6A4EE2-20A4-4E58-8CF0-9535CA2BB9BFQ33563387-EBFE365B-578F-4DBC-B4EF-DA2ECC19CC01Q33696177-C40860B1-5CEC-4877-9B6D-BEFB4EAC235BQ33844949-6FBAB286-AE6B-4E73-BD7F-F745E3A382BAQ34060040-FC2044BE-2C5B-4862-B2EC-868E170FB590Q34061568-A6E8F2DE-FFDA-45A9-B357-4497FD5412D1Q34117600-C9638EF4-C4F5-4FAF-ACCE-62ABD736A43AQ34259247-567FA074-252F-46EE-AFA7-F6C12FBDC245Q34325576-F0F5BCCD-E07D-47ED-AE31-3969871D9EB8Q34446993-4EFE590D-E53B-4A1C-BB48-330D4DF9FD1DQ34533573-D893DBCA-D4FB-448E-A35E-F9359FB4FA71Q35023098-34EDF5CC-E1A4-4591-A977-0964E24C5994Q35048929-E65BF1A1-6324-46C7-A138-4DDCFA320E1FQ35125001-81E723AD-95DD-4964-85E0-3166727CE4DFQ35137389-824B95F0-9282-4E38-ADF3-CCE6EA2D4C9DQ35148844-7882399F-EDA9-4CC9-BA95-FEFC5DE0F3CCQ35203626-5D7E47FD-4ADE-45E2-B2D6-4E06190D4BC5Q35794829-573613C4-BE3C-4BA8-85E8-42B11591D5A5Q35834043-BB631C80-9844-4762-81ED-7DF237768731Q36063245-A6DAB422-F1C2-4055-931E-5944919DDD65Q36157306-E046644F-2C13-438E-93AA-1E87F29915CAQ36335146-4B3B8CA3-6810-4969-84DE-AB08A2CDEA5DQ36873680-E193350B-6E2E-4A5A-AE5B-8F2295A15BECQ36928061-C8CBB24D-09E2-407B-8DD0-54D66E7839EAQ36958208-0B7C06B2-FE67-4B4B-80CA-2094275DCC85Q37076753-FEF1138B-EFBC-402C-BA0A-CD858A4145F1Q37146578-B00CA17C-2180-4F7D-830E-DDFB4245A728Q37260477-FB4ED477-F221-4B5A-B9A3-4BD63D7BFC75
P2860
The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The Lewy body in Parkinson's d ...... of alpha-synuclein aggregates.
@en
The Lewy body in Parkinson's d ...... of alpha-synuclein aggregates.
@nl
type
label
The Lewy body in Parkinson's d ...... of alpha-synuclein aggregates.
@en
The Lewy body in Parkinson's d ...... of alpha-synuclein aggregates.
@nl
prefLabel
The Lewy body in Parkinson's d ...... of alpha-synuclein aggregates.
@en
The Lewy body in Parkinson's d ...... of alpha-synuclein aggregates.
@nl
P2093
P2860
P1433
P1476
The Lewy body in Parkinson's d ...... of alpha-synuclein aggregates.
@en
P2093
Fumiaki Mori
Hitoshi Takahashi
Koichi Wakabayashi
Kunikazu Tanji
P2860
P304
P356
10.1111/J.1440-1789.2007.00803.X
P577
2007-10-01T00:00:00Z